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Abstract 
Identifying small molecules that induce the disruption of constitutive protein–protein 
interfaces is a challenging objective. Here, a targeted biophysical screening cascade 
was employed to specifically identify small molecules that could disrupt the 
constitutive, homodimeric protein–protein interface within CK2β. This approach 
could potentially be applied to achieve subunit disassembly of other homo–oligomeric 
proteins as a means of modulating protein function. 
  
Introduction 
Protein kinase CK2 is a pleiotropic, ubiquitous and intrinsically active eukaryotic 
Ser/Thr protein kinase that is overexpressed in various cancer types.1 In humans, CK2 
forms a heterotetrameric complex (α2/β2) consisting of two catalytic subunits (CK2α 
or α) attached to a dimer of regulatory subunits (CK2β or β2).2 The unique molecular 
architecture of the CK2 holoenzyme could be exploited in the design of inhibitors that 
do not target the ATP site and thus provide a more specific mode of action, prompting 
the discovery of various non–ATP–competitive inhibitors against CK2.3 In particular, 
significant efforts have been devoted to the development of compounds that disrupt 
the transient, hetero–oligomeric protein–protein interaction (PPI) between CK2α and 
CK2β.4–6 Given that the function of proteins critically depend on a correct 
oligomerization state, and the importance of CK2β in modulating the catalytic activity 
and substrate specificity of CK2α, disruption of the constitutive, homodimeric PPI 
within CK2β represents an alternative approach to interfere with CK2 function.7,8  
 
Developing small molecule inhibitors to disrupt PPIs is a challenging task due to the 
typically extended and flat topology of contact surfaces, often devoid of the well–
defined deep clefts that are characteristic of many enzyme active sites.9–11 The 
difficulty is compounded by the fact that the interacting surfaces of protein partners 
are frequently segmented.12 However, recent successes in the development of PPI 
inhibitors have shown that PPIs are amenable to targeting by small molecules.13 
While the majority of the PPI inhibitors disrupt transient, hetero–oligomeric PPIs, 
only a comparatively few cases of small–molecule PPI inhibitors that target 
constitutive, homo–oligomeric interfaces have been reported.13–20 
 
Considering that achieving small–molecule inhibition of transient, hetero–oligomeric 
PPIs is already an inherently challenging effort, the search for inhibitors that disrupt 
the constitutive oligomeric interfaces within a protein is a potentially more difficult 
undertaking, in part due to the typically higher affinity, larger interfaces, and greater 
hydrophobic character than that of constitutive PPIs.21,22 Interestingly, the 
hydrophobicity and the structural plasticity of constitutive interfaces can enable 
small–molecule binding to form structurally defined complexes.14 Thus far, small–
molecule oligomeric disruptors (e.g. SPD304, BIO8898, 6–hydroxydopa) were 
discovered using a combinatorial library or high–throughput library screen and 
targeted approach, with further studies revealing their allosteric mode of inhibition.14–
16,18–20 Only one recent study employed a fragment–based functional screen to identify 
compounds whose inhibitory basis was disruption of the dimeric architecture of a 
viral protease, rather than binding to the active site.17 
 
In contrast to traditional high–throughput screening, the use of a smaller compound 
library in a fragment–based screen offers the advantage of a more efficient and rapid 
exploration of weaker binding, but ligand–efficient chemical moieties.23 Here, a 
biophysical fragment–screening cascade was performed to specifically identify and 
validate fragments that are able to disrupt the CK2β dimer interface. This approach 
involved the sequential application of fluorescence–based thermal shift to screen for 
preliminary hits, ligand–observed NMR assays for validation of fragment binding, 
and native mass spectrometry (MS) to confirm the ability of fragments to induce 
dimeric disruption. An orthogonal biophysical assay using homodissociation 
isothermal titration calorimetry (ITC) was also developed to probe structure–activity 
relationships (SAR) governing dimerization affinity in a CK2β mutant and confirm 
the dimer–disrupting nature of the fragments. 
 
  
Results and Discussion 
 
Thermal shift screening  
The first screening technique is a fluorescence–based thermal shift (FTS) assay, 
which monitors protein thermal denaturation by using an extrinsic, environmentally–
sensitive probe, for which the fluorescence increases upon binding to the unfolded 
protein.24,25 As a protein is incrementally heated, it unfolds and exposes its 
hydrophobic core. Unfolded protein provides more non–polar regions for protein–dye 
interaction, causing a rise in the fluorescence intensity. Fragments that bind to and 
stabilize or destabilize the protein will increase or lower the melting temperature (Tm), 
respectively. The difference between the Tm of the protein–fragment complex and the 
Tm of the apo protein represents the thermal shift (ΔTm). 
 
As fluorescence–based thermal shift assay is the first screening technique, its ability 
to inform whether small molecules that induced the disruption of constitutive 
oligomeric interfaces would produce thermal destabilization, corresponding to a loss 
of stabilizing subunit interactions, when incubated with the protein target was first 
evaluated (Figure 1a). Two eukaryotic macromolecular targets, Rad521–209 and TNF–
α were selected for validation studies, as small molecules that disrupt the constitutive 
oligomeric interfaces in both proteins have been characterized.14,16 Binding of 6–
hydroxydopa to Rad521–209 induced an undecameric–to–dimeric transition (Figure 
1b).16 No melting curve could be observed for Rad521–209, indicating that it has an 
extremely high thermal stability (Tm > 99.0 ºC), which is in agreement with published 
data demonstrating the especially high melting temperature of a similar Rad52 
construct, Rad521–192 (Figure 1c).26 In the presence of 6–hydroxydopa, Rad521–209 
displayed an observable melting transition, registering a Tm of 85.0 ºC (Figure 1c). 
SPD304, discovered from a combinatorial library screen, was observed to eject a 
monomer of native trimeric TNF–α by complexing with a dimer of TNF–α (Figure 
1d).14 Similarly, the apparent Tm of TNF–α decreased from 65 ºC (putatively assigned 
due to the broad melt curve, which prevents precise Tm determination) to 61.0 ºC in 
the presence of SPD304 (Figure 1e). The melting temperature (Tm) of both proteins 
decreased in the presence of the small–molecule oligomeric disruptor, supporting the 
use of negative thermal shifts to identify molecules that cause a de–homooligomeric 
transition. 
 In light of these results, 800 fragments were screened at 5 mM against CK2β. A 
histogram depicting the distribution of ΔTm induced by the fragments is shown in 
Figure 1f. The average Tm of CK2β was 54.3 ± 0.1 °C. Most of the fragments induced 
CK2β destabilization as shown by the left–skewed distribution of ΔTm values. The 
maximum stabilizing and destabilizing ΔTm from the screen was +0.8 °C and –6.0 °C, 
respectively. While no fragments induced significant positive thermal shifts, it was 
interesting to note that several fragments significantly lowered the melting 
temperature of CK2β. Fragments which induced a ΔTm < –1.5 °C for the negatively–
shifting fragments were selected for follow–up studies. Based on this threshold value, 
60 destabilizing fragment hits were identified. Fragments that produced poorly 
defined melting curves were excluded from further analysis. 
 
  
 
Figure 1. Use of fluorescence–based thermal shift assay to detect small molecules 
capable of inducing de–homooliogomerization. (a) Hypothetical scheme illustrating 
whether small–molecule (triangle) disruption of a homodimeric assembly (black) to a 
monomeric state (red) is translated to a negative thermal shift. The first derivative of 
the melting curves are shown. (b) Schematic showing the undecameric–to–dimeric 
transition of Rad521–209 induced by 6–hydroxydopa (green). (c) Rad521–209 alone 
(blue) did not produce a melting transition, indicating that its Tm was more than 99 ºC. 
In the presence of 6–hydroxydopa, Rad521–209 registered a Tm of 85.0 ºC (red). (d) 
SPD304 (blue) causes the dissociation of native trimeric TNF–α (purple) into a 
SPD304–bound dimer (pink) and monomer (yellow). (e) The melting curve of native 
trimeric TNF–α (purple) showed that it had a putative Tm of 65 ºC. In the presence of 
SPD304, the melting temperature of TNF–α decreased to 61.0 ºC (pink). (f) 
Distribution of thermal shift values induced by fragments in CK2β from the 
fluorescence–based thermal shift screen. 
  
Ligands that increase the Tm of a protein are predominantly pursued for subsequent 
validation and optimization, as they cause stabilization of the protein–ligand 
complex.27,28 In contrast, it is commonly believed that fragments that cause negative 
thermal shifts signify preferential fragment binding to the unfolded form of the 
protein, and are subsequently excluded from further analysis.27 However, this does 
not necessarily hold true for all protein systems, as seen in the validation studies using 
Rad521–209 and TNF–α and their disruptors. To our knowledge, only one fragment–
based study selected both thermally stabilizing and destabilizing fragments against 
homodimeric Mycobacterium tuberculosis BioA (an aminotransferase that uses a 
pyridoxal 5–phosphate cofactor) for follow–up studies, although no rationale was 
given for considering thermally destabilizing fragments.29,30 Only one out of the 12 
destabilizing fragments from the original screen against BioA produced a structure by 
co–crystallization.29 Subsequent SAR–by–catalog of fragment hits resulted in the 
crystallographic and thermodynamic characterization of a series of inhibitors.29,30 This 
study has shown that thermally destabilizing fragments can be inhibitors and that 
caution should be applied before rejecting negatively–shifting fragments for further 
evaluation. Furthermore, it has been suggested that thermally destabilizing fragments 
may have an additional value in promoting a more rapid degradation of the target 
protein.29 
 
Both SPD304 and 6–hydroxydopa, which promoted subunit disassembly by binding 
to a non–native form of their protein target, lowered the melting temperature of their 
protein complexes. The disruption of stabilizing subunit interactions between 
protomers in an oligomeric protein by any ligands could be expected to decrease the 
protein’s stability, which would be reflected by a lowering of its melting temperature. 
Essentially, any interpretation of FTS results must take into consideration that the 
FTS assay depends on fluorescent dye binding. Changes in the Tm are a reflection of 
changes in the fluorescent dye binding. A ligand that binds to and stabilizes a protein 
would slow both its denaturation and exposure of its hydrophobic region, causing a 
delayed rise in the fluorescence intensity to result in an increase of the Tm. On the 
contrary, a ligand that disrupts constitutive hydrophobic interfaces in an oligomeric 
protein would allow the fluorescent dye access to hydrophobic environments for 
binding, leading to an earlier increase in the fluorescence intensity to produce a 
decrease in the Tm. Structural analyses of both Rad521–209 and TNF–α revealed that 
oligomerization is largely mediated by hydrophobic interactions between the 
subunits.31,32 By causing earlier and greater exposure of hydrophobic areas upon 
subunit dissociation, SPD304 and 6–hydroxydopa stabilized non–native forms of their 
protein complex that binds the dye with higher propensity than the native form, 
thereby resulting in an early rise in the fluorescence intensity to eventuate in negative 
thermal shifts. Based on this reasoning, coupled with the hydrophobically–driven 
nature of CK2β dimerization, a possible model that fits our results is that thermally 
destabilizing fragments are causing monomerization of CK2β.33 A model to describe 
fragment–induced negative thermal shift of CK2β is presented in Figure 2. 
Alternatively, there is also a possibility that a small proportion of CK2β monomer 
could be present that provides a rapid route for unfolding. Furthermore, in the vein of 
a mechanism resembling the effect of BIO8898 on CD40, thermally destabilizing 
fragments could also bind to and distort the CK2β dimer interface without completely 
causing subunit dissociation.15 In the absence of additional experimental evidence, it 
is difficult to speculate whether dimer distortion translates to a negative thermal shift. 
However, subsequent orthogonal assays using native MS and homodissociation ITC 
would help clarify the most probable molecular mechanism. 
  
 
Figure 2. Model of fragment binding to CK2β (β2) to rationalize negative thermal 
shift. Fragment–induced monomerization of β2 results in the formation of a species 
(denoted with an asterisk) with a higher hydrophobic character that promotes earlier 
binding of the fluorescent dye, thereby resulting in negative thermal shift. L and U 
represent fragment and unfolded protein, respectively. 
 
  
The thermal shift screen can be applied to proteins that experience either reversible or 
irreversible denaturation. A reversible two–state equilibrium between the structured 
native state and the unfolded state can be used to describe protein unfolding, with the 
assumption that only these two states exist. On a sufficiently short timescale, it has 
been experimentally and computationally shown that the unfolding process is pseudo–
reversible, as it is possible to generate reasonable plots of the apparently irreversible 
denaturation process using the van’t Hoff equation, which relates changes in the 
equilibrium constant to temperature.34 Over the entire time course of a thermal shift 
experiment, the exposure of hydrophobic cores during protein unfolding would 
ultimately lead to the formation of irreversible aggregates. Therefore, a majority of 
large multi–domain proteins will eventually undergo partially or completely 
irreversible denaturation.35 Using proteins that undergo irreversible thermal protein 
denaturation, such as E. coli aspartate transcarbamoylase and the core protein of the 
lac repressor, it has been shown that the denaturation process obeys equilibrium 
thermodynamics as characterized by the van’t Hoff equation, thus resembling a 
reversible process.36,37 Furthermore, the data obtained from simulating an irreversible 
denaturation process were similar to that of a completely reversible denaturation 
model.37 Therefore, thermal shift screening could be applied to oligomeric proteins 
regardless whether they undergo reversible or irreversible denaturation. 
 
As fragments enable sampling of a larger chemical space, fragment libraries tend to 
be smaller than a high–throughput screen library.38 Thermal shift screening is rarely 
rate limiting, but could be achieved more rapidly with the use of a higher temperature 
ramp rate. In general, the magnitude of thermal shift is not strongly dependent on the 
temperature ramp rate when a heating rate between 1–8 ºC min–1 is applied. This is 
supported by a study in which thermal shifts produced by screening different 
concentrations of known ligands against nine proteins did not change significantly 
despite the use of ramp rates spanning 1–8 ºC min–1.39 It was further recommended 
that a heating rate of up to 4 ºC min–1 could be used with minimal impact on ligand 
detection for most proteins.39  
Validation of fragment binding by ligand–observed NMR spectroscopy 
Two NMR approaches could be employed to validate fragment binding to the protein 
target: ligand–observed and protein–observed NMR. Ligand–observed NMR assays 
are more popular as there is no requirement to produce isotopically labeled proteins. 
As there is no upper limit on the protein size, ligand–observed methods would be well 
suited for oligomeric proteins.40 Furthermore, the assay is straightforward, rapid, and 
has relatively low protein consumption by enabling the acquisition of multiple NMR 
assays on the same sample. The principles and applications of ligand–based NMR 
methods have been extensively reviewed.40,41 Briefly, ligand–observed NMR assays 
depend on monitoring differences in the properties of the ligand spectra (e.g. 
magnetization transfer or relaxation) upon interaction with the macromolecular target. 
Experiments based on direct or indirect magnetization transfer (saturation transfer 
difference [STD] and water–ligand observed via gradient spectroscopy 
[waterLOGSY]) and differential relaxation (Carr–Purcell–Meiboom–Gill [CPMG]) 
are commonly used in fragment–based campaigns.42–45 Performing three orthogonal 
NMR assays, each with their own advantages and disadvantages, lowers the chances 
of false positives and negatives originating from artifacts of a single NMR 
experiment. 
 
All the 60 destabilizing fragment hits identified from the thermal shift screen were 
validated for binding to CK2β using a panel of three ligand–observed 1H NMR assays 
(STD, waterLOGSY and CPMG). The NMR screen validated 45 of the 60 
destabilizing hits, representing a 75% validation rate, thus giving a good confidence 
of the binding event (Supplementary Figure 1). Among the destabilizing hits, 40 
fragments showed binding in all three NMR experiments, a further 5 fragments 
showed binding in at least two NMR experiments (Supplementary Figure 1). No 
correlation between the degree of binding observed in the NMR experiments and the 
magnitude of ΔTm values was observed (Supplementary Table 1). The magnitude of 
thermal shift is a combined function of the enthalpy change of protein unfolding, 
enthalpy change of ligand binding and ligand affinity.46 The magnitude of thermal 
shift of a set of compounds will correlate to their binding affinities only when the 
compounds possess similar binding enthalpies. This has been demonstrated by a study 
in which the rank order of affinity and binding constants of a series of chemically and 
structurally distinct β–site amyloid precursor protein–cleaving enzyme 1 (BACE1) 
inhibitors obtained using FTS and ITC were found to correlate well, particularly 
because the ligands had similar binding enthalpies.25 Had the binding enthalpies of the 
BACE1 inhibitors been very different, the affinity ranking based on the thermal shift 
values would be inaccurate. This implies that the ΔTm value associated with fragment 
binding does not necessarily correlate with its binding affinity. As the CK2β fragment 
hits are chemically and structurally different, it is possible that they have different 
binding enthalpies. This means that fragments with the same binding affinity, but with 
different binding enthalpies will generate different ΔTm values. Hence, the extent of 
thermal destabilization cannot be used as a measure of its binding affinity, and, by 
extension, its degree of binding in NMR assays. 
  
Native MS reveals dimeric dissociation of CK2β by destabilizing fragments   
Native or non–denaturing nanoelectrospray ionization–mass spectrometry (nanoESI–
MS) provides rapid, sensitive, label–free and accurate detection of non–covalent 
assemblies, such as protein oligomers or protein–ligand complexes, in the gas phase.47 
Various studies have shown that gas–phase proteins retain folded conformations and 
possess structural features that approximate to those in the solution state, thus 
providing a simulacrum of solution–phase conditions.48 The high separation 
efficiency of MS is especially relevant for examination of the oligomeric populations 
of proteins in the gas phase.49 For similar protein species, it has been shown that there 
is good agreement of the oligomeric distribution obtained using gas–phase and 
solution–phase methods, although the caveat that similar oligomeric forms may have 
different efficiency of ionization, transmission and detection must be recognized.50–53 
Nevertheless, adopting a native MS approach enables us to address the presence and 
degree of oligomeric state perturbation by thermally destabilizing fragments, which 
could serve as an indication of the dimer–disrupting potency of fragments. 
 
Native MS was used to study the effect on the oligomerization state of CK2β of the 
40 destabilizing fragment hits that were shown to bind to CK2β in all three ligand–
observed NMR assays. Native mass spectra of 16 μM CK2β in the presence of 5% 
(v/v) DMSO were acquired under non–denaturing conditions by nanoESI–MS. CK2β 
produced two well–resolved narrow charge state distributions corresponding to 
monomeric CK2β (observed mass = 22,962 ± 17 Da; calculated mass = 22,945 Da) 
and dimeric CK2β (observed mass = 45,938 ± 17 Da; calculated mass = 45,890 Da), 
with lowly charged ions to signify that they retain folded, native–like structures 
(Figure 3). The predominant species is dimeric CK2β, which is consistent with 
published structural data.33,54 
 
In the presence of 2 mM fragment, native MS showed that 18 out of the 40 
compounds induced a higher population of monomeric CK2β by promoting the 
disassembly of dimeric CK2β to different extents (18–71% monomerization) (Figure 
3). 1 and 2 had the greatest effects on dimer disruption, inducing 71% and 67% 
monomerization of CK2β, respectively. Both 1 and 2 possess the 5–substituted 
pyrazole core, suggesting the importance of this chemical scaffold in mediating dimer 
disruption. Furthermore, native MS experiments showed 3 and 4, bearing the pyrazole 
scaffold, to cause 49% and 24% monomerization of CK2β, respectively. Apart from 
pyrazole–based fragments, compounds with quinoline (5–7) and naphthol (8–11) 
cores are also well represented (Supplementary Figure 2). There was no correlation 
between extent of monomerization and thermal shift, as the magnitude of thermal 
shift induced by a fragment is not necessarily proportional to its affinity for the 
protein.46 
 
The two CK2β subunits associate via a zinc–finger containing dimerization domain.33 
Ablation of the zinc finger, by mutation of the zinc–coordinating cysteine residues, 
resulted in dimerization–defective CK2β.55 The observed mass of monomeric CK2β 
(22,962 Da) is in close agreement with the theoretical mass of monomeric CK2β with 
one Zn2+ bound (22,945 Da), showing that fragments do not cause monomerization by 
metal sequestration. Importantly, the narrow charge state distribution observed for 
monomeric CK2β signifies that the destabilizing fragments were able to cause dimeric 
disruption of CK2β without denaturing the protein. Furthermore, the clear observation 
of an enrichment in the monomeric species shows that CK2β is converted to the 
monomer at the fragment concentration used. This argues against the possibility that 
fragments were merely distorting the CK2β dimer interface without inducing 
dissociation (reminiscent of the effect of BIO8898 on CD40), as an increase in the 
intensity of the monomeric species would not be expected.15 However, it is possible 
that the fragments could be both distorting and weakening the CK2β dimer interface 
to the extent of causing dissociation. 
 
Information about binding stoichiometry could not be extracted from the native mass 
spectra, as only non–complexed monomeric and dimeric CK2β were detectable. This 
is not unusual given that the fragments may be potentially mediating the disruption of 
dimeric CK2β by mainly engaging in hydrophobic interactions with residues at the 
dimer interface. The hydrophobic effect does not apply for proteins in the gaseous 
phase, and protein–ligand complexes bound primarily by hydrophobic interactions 
tend to dissociate in the gas phase.56,57 
 
 
 
Figure 3. Native mass spectra of 16 μM CK2β, acquired in 0.5 M ammonium acetate 
pH 8.0, in the presence of validated thermally destabilizing fragments (2 mM). The 
percentage of CK2β monomerization induced by a fragment is indicated in orange 
text below the compound number. Charge states are colored and indicated with 
symbols. The observed mass and identity of each species are indicated beside the 
symbols. Only one charge state of each species is indicated in the spectra. 
  
Structural features of the CK2β dimer interface  
Four highly conserved cysteine residues (Cys109, Cys114, Cys137 and Cys140) in a 
CK2β protomer are involved in zinc coordination to form a zinc–binding motif that 
constitutes the dimerization domain.33 The dimerization interface of CK2β is largely 
driven by hydrophobic interactions, with the β/β core composed of non–polar residues 
(Pro110, Val112, Leu124, Val143, and the hydrophobic moieties of Tyr113 and 
Tyr144) (Supplementary Figure 3). Salt–bridge and hydrogen–bonding interactions 
(Arg111 and Asp142, backbone carbonyl and amino groups of Pro110 and Thr145, 
and Val143 and Val112, respectively) also serve to stabilize the dimer 
(Supplementary Figure 3). Dimerization of CK2β results in the burial of 1,766 Å2 per 
protomer, a value consistent with that expected of a permanent PPI, establishing 
CK2β as an obligate dimer.9,33 
 
Homodissociation ITC 
A homodissociation ITC assay was developed in order to provide an orthogonal, 
solution–phase approach of confirming the mechanism of fragment–induced dimer–
disruption and examine structure–activity relationships governing dimerization 
affinity. In homodissociation ITC, a concentrated solution of oligomer is titrated into 
a buffer cell using a series of small–volume injections.58 The initial few injections 
lead to huge dilutions of the protein concentration, and therefore promote oligomeric 
dissociation. Each injection typically yields an endothermic heat pulse, which 
progressively decreases in intensity over the entire course of titration due to an 
increase in the protein concentration in the cell disfavoring dissociation. The oligomer 
dissociation constant is determined by fitting the data to a dissociation model, 
operating with the assumption that the monomer–dimer equilibrium is reversible 
under the experimental conditions. 
 
Given the weak affinity expected for fragment binding, a strategy of directed 
mutagenesis was adopted to systematically reduce the strength of the dimeric CK2β 
interface (Supplementary Figure 3 and Supplementary Figure 4). Being core 
hydrophobic residues that significantly contribute to the stabilization of the dimer 
interface, Pro110 and Val143 were mutated to aspartate to attenuate hydrophobic 
interactions and introduce electrostatic repulsion to weaken subunit association. This 
generated a CK2β mutant, which displayed concentration–dependent dimerization. 
CK2β P110D/V143D was shown to exist in a monomer–dimer equilibrium with a KD 
of 90 μM in the presence of the vehicle control, DMSO (Figure 4a).  
 
Generally, all the 18 fragments that induced monomerization of CK2β dimer in native 
MS experiments decreased the dimerization affinity of the double mutant, suggesting 
that they disrupted the dimeric interaction in CK2β P110D/V143D (Supplementary 
Table 2). This was also supported by the appearance of the dissociation isotherms, 
wherein the intensities of the endothermic heat pulses increased and the dilution 
isotherms became more attenuated in the presence of fragments, indicating greater 
dimer dissociation (Supplementary Figure 5). There is no correlation between the 
magnitude of thermal shift, or the degree of monomerization obtained from native MS 
experiments and the dimerization affinity (Supplementary Table 1). This could be 
attributed to the use of a mutant construct with different interfacial properties from 
that of wild–type CK2β. Out of all the 18 fragments tested, 2 was the most potent in 
mediating dimerization disruption (KD = 1,010 μM). Surprisingly, 1 only caused a 
modest weakening of dimerization affinity (KD = 200 μM), despite inducing the 
greatest extent of monomerization in the native MS assay. This suggests that the 
binding site of 1 could have been affected by the double mutation, and that 2 might be 
binding to a different region of CK2β from 1. 
 
Exploration of structure–activity relationships of selected thermally destabilizing 
fragments 
Further screening of structural analogs of 4 and 16, available from our in–house 
compound collection, resulted in the identification of more potent dimer–disrupting 
compounds. The effects of functional group substitutions on 4 (KD = 460 μM) (Figure 
4b) and 16 (KD = 230 μM) (Figure 4c) were explored, with the KD values reflecting 
the apparent affinity for dimer formation, and not the affinity of compound binding. 
 
Changing the chloro group in 4 to a hydroxyl group preserved a similar dimer–
disrupting potency (4a, KD = 410 μM) (Figure 4b). By combining the observation that 
4a was able to hinder dimerization of the double mutant with the fact that 1 
demonstrated the greatest monomerizing effect in native MS, we examined whether 
4b, with the 3–bromo and 5–phenyl groups in 1 replaced with phenolic groups, would 
have a greater potency towards effecting dimeric disruption. Indeed, 4b caused a 
significantly decrease in the dimerization affinity (KD = 1,200 μM) (Figure 4b), 
suggesting that polar interactions and hydrophobic or aromatic stacking interactions 
contribute to weakening dimeric association in the CK2β double mutant. 
 
Replacing the methylene linker in 16 with an NH group caused approximately 2–fold 
increase in dimer–disrupting effect (16a, KD = 490 μM), suggesting a role for 
hydrogen bonding interactions in effecting subunit disassembly (Figure 4c). 
Incorporation of functional groups at different positions on the phenyl ring, however, 
had different effects. Addition of an ester group at the para position of the phenyl ring 
resulted in a decrease in dimer–disrupting potency (16b, KD = 230 μM). Substitutions 
at the meta position of the phenyl ring of 16a were generally more favorable for dimer 
disruption than para substitutions as shown by the lower dimerization affinity induced 
by 16c (KD = 690 μM) and 16d (KD = 350 μM) than 16b (Figure 4c). 
 
The SAR studies have demonstrated that the CK2β P110D/V143D mutant could 
potentially serve as a surrogate protein for the development of fragments into more 
potent compounds that disrupt the CK2β interface. In addition, the other CK2β mutant 
proteins provide a range of weaker homodimeric interfaces (i.e. CK2β P110D/R111D, 
CK2β P110D/V112D/V143D) (Supplementary Figure 3c) that could be useful for the 
systematic screening and development of compounds that destabilize the 
homodimeric interface of wild–type CK2β. 
 
  
 
Figure 4. Thermally destabilizing fragments decreased the dimerization affinity in 
CK2β P110D/V143D in homodissociation ITC experiments. (a) Homodissociation 
isotherm of CK2β P110D/V143D in 5% (v/v) DMSO. (b) Homodissociation 
isotherms of 4 and its analogs (4a and 4b). (c) Homodissociation isotherms of 16 and 
its analogs (16a–16d). The top and bottom panels of each ITC profile illustrate the 
raw calorimetric data and the integrated heats per injection, respectively. 
 
  
Potential consequences of CK2β monomerization 
Having established that thermally destabilizing fragments drive the dimeric–to–
monomeric transition of CK2β, what could be the potential consequences of such an 
effect? Despite being able to interact with CK2α to form the heterotetramer, the CK2β 
P110D/V143D mutant caused decreased the catalytic activity of CK2α, highlighting 
that the modulation of CK2α catalytic activity by CK2β is highly dependent on a 
proper dimeric architecture of CK2β.59 Cell studies have shown that a dimerization–
incompetent CK2β, generated by mutating two conserved cysteine residues of the 
zinc finger to serine, was defective in forming the α2/β2 heterotetramer and 
experienced faster degradation.55 Together, these studies suggest that dimer–
disrupting fragments could promote CK2β degradation and an attenuation of CK2α 
catalytic activity through favoring the formation of the CK2β monomer. 
 
Conclusion 
In summary, this study demonstrated the application of a fragment–based approach to 
specifically identify small molecules with the ability to induce disruption of the CK2β 
dimer. Orthogonal biophysical experiments involving native MS and 
homodissociation ITC support a mechanism that is consistent with fragment–induced 
dimeric disruption. Future work in obtaining co–crystal structures of CK2β with the 
destabilizing fragments would help to elucidate the structural determinants of dimeric 
disruption and enable structure–guided optimization of compounds. The approach 
described in this study could potentially be applied to discover small molecules to 
disrupt other therapeutically relevant and challenging homo–oligomeric proteins as a 
means of modulating protein function. 
 
  
Methods 
 
Expression and purification of CK2β. Bacterial expression vectors encoding 
sequences for Homo sapiens CK2β1–193 and CK2β1–193 mutants (all encoded within 
pGEX–6P–1) were transformed into E. coli BL21(DE3). A freshly transformed 
colony was inoculated into LB broth supplemented with ampicillin and grown 
overnight at 37 °C. After inoculation of overnight culture, LB cultures were grown at 
37 °C, induced with 0.3 mM IPTG after reaching an optical density of 0.6 (λ = 600 
nm) and allowed overnight expression at 18 °C. Harvested cell pellets were 
suspended and sonicated in cold lysis buffer A (50 mM Tris–HCl pH 8.5, 200 mM 
NaCl, 5 mM β–mercaptoethanol). Cellular debris was removed by centrifugation 
(20,000 rpm, 30 min, 4 °C) and CK2β was purified using glutathione sepharose 4B 
beads (GE Healthcare). The beads were washed with 20 column volumes of cold 
buffer A and incubated with 3C protease at 4 °C overnight to cleave the GST tag. The 
digested protein solution was loaded onto a HiTrap Q column (GE Healthcare) and 
fractionated over a 0–1000 mM NaCl gradient buffered with 50 mM Tris–HCl pH 8.5 
and 2 mM β–mercaptoethanol. CK2β–containing fractions, analyzed by SDS–PAGE, 
were concentrated and loaded onto a Superdex 200 26/60 column (GE Healthcare) 
equilibrated with cold buffer B (50 mM Tris–HCl pH 8.5, 500 mM NaCl, 2 mM β–
mercaptoethanol). Fractions containing pure CK2β were combined and concentrated. 
 
Site–directed mutagenesis. Mutagenesis of Homo sapiens CK2β1-193 to generate the 
P110D, P110D/R111D, P110D/V143D and P110D/V112D/V143D mutants was 
performed using the Q5 site–directed mutagenesis kit (New England Biolabs) 
according to the instruction manual. Vectors of mutant clones were sequenced (DNA 
Sequencing Facility, University of Cambridge) to verify correct incorporation of 
mutation. 
 
Expression and purification of Rad521–209. The expression vector encoding Homo 
sapiens Rad521–209 (cloned into pET28) was transformed into E. coli BL21–
CodonPlus(DE3)–RIPL. Fresh transformants were inoculated into LB broth 
supplemented with kanamycin and chloramphenicol, and grown overnight at 37 °C. 
After inoculation of overnight culture, LB cultures were grown at 37 °C, induced with 
1 mM IPTG after reaching an optical density of 0.6 (λ = 600 nm) and allowed 
expression at 30 °C for 4 hours. Cell pellets were suspended and sonicated in buffer A 
(50 mM Tris–HCl pH 7.5, 500 mM KCl). Debris was removed by centrifugation 
(20,000 rpm, 30 min, 4 °C) and Rad521–209 was purified using Ni–NTA beads (GE 
Healthcare). The beads were washed with buffer A supplemented with 20 mM 
imidazole, and eluted with buffer A supplemented with 300 mM imidazole. The 
eluted protein solution was concentrated and loaded onto a Superdex 200 26/60 
column (GE Healthcare) equilibrated with buffer B (50 mM Tris–HCl pH 7.5, 200 
mM KCl, 2 mM β–mercaptoethanol). Fractions containing Rad521–209 were combined 
and loaded onto a HiTrap Heparin HP (GE Healthcare) and washed with buffer B. 
Rad521–209 was eluted using a 200–1000 mM KCl gradient over 20 column volumes. 
Fractions containing pure Rad521–209, as analyzed by SDS–PAGE, were combined 
and concentrated. 
 
Protein quality assessment. All proteins produced in–house were assessed for their 
identity, purity, monodispersity and oligomeric state using a combination of SDS–
PAGE, amino acid analysis, dynamic light scattering and native mass spectrometry 
(Supplementary Information). 
 
Fluorescence–based thermal shift. The thermal shift assay was performed on a 
LightCycler 480 Real–Time PCR System (Roche) in 96–well white plates (Roche). 
For Rad521–209, each well contained 40 μL of 2 μM Rad521–209 and 2.5x SYPRO 
Orange in 50 mM Tris–HCl pH 7.5, 200 mM KCl, with 6–hydroxydopa (Santa Cruz 
Biotechnology) added to a final concentration of 2.5 mM in 5% (v/v) DMSO. For 
TNF–α (Gibco), each well contained 40 μL of 10 μM TNF–α and 5x SYPRO Orange 
in 50 mM Tris–HCl pH 8.5, 200 mM NaCl, with SPD304 (Cambridge Bioscience) 
added to a final concentration of 200 μM in 5% (v/v) DMSO. For CK2β, each well 
contained 40 μL of 6 μM CK2β and 5x SYPRO Orange in 50 mM Tris–HCl pH 8.5, 
50 mM NaCl. Fragments were tested at a final concentration of 5 mM in 5% (v/v) 
DMSO. Each plate was sealed with an optically clear foil and centrifuged for 1 
minute at 1,000 rpm before performing the assay. The plates were heated from 37–85 
ºC at approximately 2 ºC min–1. The fluorescence intensity was measured with λex = 
480 nm and λem = 580 nm. The melting temperature (Tm) was obtained by determining 
the minimum of the first derivative curve of the melt curve. The thermal shift (ΔTm) 
was determined by computing the difference between the Tm of the protein in the 
presence of compound and that of the protein in the presence of 5% (v/v) DMSO. 
 
Ligand–observed 1H NMR. Ligand–observed 1H NMR experiments were performed 
at 278 K on a 700 MHz Bruker NMR spectrometer fitted with a 5 mm triple TXI 
cryoprobe. Spectra were analyzed using the Bruker TopSpin 3.2 software. Samples 
were made up to 200 μL in 3 mm capillaries with d4–trimethylsilylpropionic acid 
(TSP) for calibration. Negative control (no protein) experiments were performed for 
each compound tested. All binding experiments were carried out using 20 μM CK2β 
in 50 mM Tris–HCl pH 8.5, 50 mM NaCl, 20 μM TSP, 10% (v/v) D2O and 0.01% 
(v/v) Tween–20. Fragments were tested at 2 mM in a final concentration of 2–4% 
(v/v) d6–DMSO in binding experiments.  
 
Native nanoESI–MS. Spectra were recorded on a Synapt HD mass spectrometer 
(Waters) modified for studying high masses. CK2β was exchanged into 0.5 M 
ammonium acetate solution pH 8.0 using Micro Bio–Spin 6 chromatography columns 
(Bio–Rad). 2 mM of a fragment was incubated with 16 μM CK2β for 30 min before 
analysis. The final DMSO concentration was 5% (v/v). 2.5 μL of protein solution was 
electrosprayed from a borosilicate emitter (Thermo Scientific). Typical conditions 
were capillary voltage 1.6–1.8 kV, cone voltage 60–80 V, collision voltage 10−20 V, 
with backing pressure 3–4 mbar and source temperature of 20 °C. Spectra were 
calibrated externally using cesium iodide. Data acquisition and processing were 
performed using MassLynx 4.1. 
 
Homodissociation ITC. Homodissociation ITC experiments were performed using 
MicroCal Auto–iTC 200 (Malvern) at 25 ºC. The concentration of CK2β 
P110D/V143D was selected such that the heats of dissociation afforded a good signal 
window and that baseline is reach in the presence of the vehicle control, indicating no 
further dissociation. The syringe solution consisted of 600 μM CK2β P110D/V143D 
incubated with 5 mM fragment in 50 mM Tris–HCl pH 8.5, 50–500 mM NaCl. The 
cell solution consisted of 50 mM Tris–HCl pH 8.5, 50–500 mM NaCl. Both the 
syringe and cell solutions contained DMSO at a final concentration of 5–8% (v/v). 
The titration consisted of 19 injections of 2 μL of the syringe solution every 120 s. 
Each fragment–protein mixture was subjected to a single titration. Errors for quoted 
KD values represent errors of the curve fit from a single experiment. Data were fitted 
and analyzed using the dissociation model in the MicroCal PEAQ–ITC software 
(Malvern).60  
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